Population clinical pharmacology of children : modelling covariate effects
Population modelling using mixed effects models provides a means to study variability in paediatric drug responses among individuals representative of those in whom the drug will be used clinically. Explanatory covariates explain the predictable part of the between-individual variability. Growth and...
Gespeichert in:
Veröffentlicht in: | European journal of pediatrics 2006-12, Vol.165 (12), p.819-829 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 829 |
---|---|
container_issue | 12 |
container_start_page | 819 |
container_title | European journal of pediatrics |
container_volume | 165 |
creator | ANDERSON, Brian J ALLEGAERT, Karel HOLFORD, Nicholas H. G |
description | Population modelling using mixed effects models provides a means to study variability in paediatric drug responses among individuals representative of those in whom the drug will be used clinically.
Explanatory covariates explain the predictable part of the between-individual variability. Growth and development are two major aspects of children not seen in adults. These aspects can be investigated by using size and age as covariates. Problems attributable to co-linearity can be approached by using size as the first covariate. Size standardisation is achieved using allometric scaling, a mechanistic approach that has a strong theoretical and empirical basis. Age is used to describe the maturation of clearance. The quantitative models (linear, exponential, first-order, variable slope sigmoidal) used to describe this maturation process vary depending on the span of the ages under investigation. Measures of response are not always straightforward and can be more difficult to quantify in children.
Covariate investigation in children is improving the understanding of developmental aspects of drug disposition and effects in the paediatric population, ultimately leading to more effective use of medications. |
doi_str_mv | 10.1007/s00431-006-0189-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68978925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68978925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-72bc03cea72ced25f76427ddb3d2ad3097650a7dd2a4ea6ccfeb12abadd4441a3</originalsourceid><addsrcrecordid>eNpdkE1L5TAUhoPMoHfUH-BGyoCz68w5SW7SuBNxvhDGha7DaZJqpW2uSSv6743cC8KsDhye9-XlYewE4TsC6B8ZQAqsAVQN2Jj6ZY-tUApeI2j1ia1ASKgVGnPAvuT8CCVjsNlnB6ga0JqbFft7EzfLQHMfp8oN_dQ7GqrNA6WRXBzi_WsVu8o99INPYarOqzH6MBTuvnLxmVJPc6hC1wU35yP2uaMhh-PdPWR3P69uL3_X1_9-_bm8uK6daHCuNW8dCBdIcxc8X3daSa69b4Xn5AUYrdZA5cFJBlLOdaFFTi15L6VEEofs27Z3k-LTEvJsxz67soqmEJdsVWN0Y_i6gF__Ax_jkqayzXKOBtE0ukC4hVyKOafQ2U3qR0qvFsG-W7Zby7ZYtu-W7UvJnO6Kl3YM_iOx01qAsx1AuQjtEk2uzx9cw5UEzcUb2vSGDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221911987</pqid></control><display><type>article</type><title>Population clinical pharmacology of children : modelling covariate effects</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>ANDERSON, Brian J ; ALLEGAERT, Karel ; HOLFORD, Nicholas H. G</creator><creatorcontrib>ANDERSON, Brian J ; ALLEGAERT, Karel ; HOLFORD, Nicholas H. G</creatorcontrib><description>Population modelling using mixed effects models provides a means to study variability in paediatric drug responses among individuals representative of those in whom the drug will be used clinically.
Explanatory covariates explain the predictable part of the between-individual variability. Growth and development are two major aspects of children not seen in adults. These aspects can be investigated by using size and age as covariates. Problems attributable to co-linearity can be approached by using size as the first covariate. Size standardisation is achieved using allometric scaling, a mechanistic approach that has a strong theoretical and empirical basis. Age is used to describe the maturation of clearance. The quantitative models (linear, exponential, first-order, variable slope sigmoidal) used to describe this maturation process vary depending on the span of the ages under investigation. Measures of response are not always straightforward and can be more difficult to quantify in children.
Covariate investigation in children is improving the understanding of developmental aspects of drug disposition and effects in the paediatric population, ultimately leading to more effective use of medications.</description><identifier>ISSN: 0340-6199</identifier><identifier>EISSN: 1432-1076</identifier><identifier>DOI: 10.1007/s00431-006-0189-x</identifier><identifier>PMID: 16807729</identifier><identifier>CODEN: EJPEDT</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Age ; Analgesics ; Biological and medical sciences ; Body Surface Area ; Body Weight ; Child ; Creatinine ; Creatinine - blood ; Fractals ; General aspects ; Glomerular Filtration Rate ; Humans ; Investigations ; Medical sciences ; Metabolic Clearance Rate ; Metabolism ; Models, Biological ; Pediatrics ; Pharmacodynamics ; Pharmacokinetics ; Pharmacology</subject><ispartof>European journal of pediatrics, 2006-12, Vol.165 (12), p.819-829</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer-Verlag 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-72bc03cea72ced25f76427ddb3d2ad3097650a7dd2a4ea6ccfeb12abadd4441a3</citedby><cites>FETCH-LOGICAL-c381t-72bc03cea72ced25f76427ddb3d2ad3097650a7dd2a4ea6ccfeb12abadd4441a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18264072$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16807729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ANDERSON, Brian J</creatorcontrib><creatorcontrib>ALLEGAERT, Karel</creatorcontrib><creatorcontrib>HOLFORD, Nicholas H. G</creatorcontrib><title>Population clinical pharmacology of children : modelling covariate effects</title><title>European journal of pediatrics</title><addtitle>Eur J Pediatr</addtitle><description>Population modelling using mixed effects models provides a means to study variability in paediatric drug responses among individuals representative of those in whom the drug will be used clinically.
Explanatory covariates explain the predictable part of the between-individual variability. Growth and development are two major aspects of children not seen in adults. These aspects can be investigated by using size and age as covariates. Problems attributable to co-linearity can be approached by using size as the first covariate. Size standardisation is achieved using allometric scaling, a mechanistic approach that has a strong theoretical and empirical basis. Age is used to describe the maturation of clearance. The quantitative models (linear, exponential, first-order, variable slope sigmoidal) used to describe this maturation process vary depending on the span of the ages under investigation. Measures of response are not always straightforward and can be more difficult to quantify in children.
Covariate investigation in children is improving the understanding of developmental aspects of drug disposition and effects in the paediatric population, ultimately leading to more effective use of medications.</description><subject>Age</subject><subject>Analgesics</subject><subject>Biological and medical sciences</subject><subject>Body Surface Area</subject><subject>Body Weight</subject><subject>Child</subject><subject>Creatinine</subject><subject>Creatinine - blood</subject><subject>Fractals</subject><subject>General aspects</subject><subject>Glomerular Filtration Rate</subject><subject>Humans</subject><subject>Investigations</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate</subject><subject>Metabolism</subject><subject>Models, Biological</subject><subject>Pediatrics</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><issn>0340-6199</issn><issn>1432-1076</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkE1L5TAUhoPMoHfUH-BGyoCz68w5SW7SuBNxvhDGha7DaZJqpW2uSSv6743cC8KsDhye9-XlYewE4TsC6B8ZQAqsAVQN2Jj6ZY-tUApeI2j1ia1ASKgVGnPAvuT8CCVjsNlnB6ga0JqbFft7EzfLQHMfp8oN_dQ7GqrNA6WRXBzi_WsVu8o99INPYarOqzH6MBTuvnLxmVJPc6hC1wU35yP2uaMhh-PdPWR3P69uL3_X1_9-_bm8uK6daHCuNW8dCBdIcxc8X3daSa69b4Xn5AUYrdZA5cFJBlLOdaFFTi15L6VEEofs27Z3k-LTEvJsxz67soqmEJdsVWN0Y_i6gF__Ax_jkqayzXKOBtE0ukC4hVyKOafQ2U3qR0qvFsG-W7Zby7ZYtu-W7UvJnO6Kl3YM_iOx01qAsx1AuQjtEk2uzx9cw5UEzcUb2vSGDA</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>ANDERSON, Brian J</creator><creator>ALLEGAERT, Karel</creator><creator>HOLFORD, Nicholas H. G</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>Population clinical pharmacology of children : modelling covariate effects</title><author>ANDERSON, Brian J ; ALLEGAERT, Karel ; HOLFORD, Nicholas H. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-72bc03cea72ced25f76427ddb3d2ad3097650a7dd2a4ea6ccfeb12abadd4441a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Age</topic><topic>Analgesics</topic><topic>Biological and medical sciences</topic><topic>Body Surface Area</topic><topic>Body Weight</topic><topic>Child</topic><topic>Creatinine</topic><topic>Creatinine - blood</topic><topic>Fractals</topic><topic>General aspects</topic><topic>Glomerular Filtration Rate</topic><topic>Humans</topic><topic>Investigations</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate</topic><topic>Metabolism</topic><topic>Models, Biological</topic><topic>Pediatrics</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ANDERSON, Brian J</creatorcontrib><creatorcontrib>ALLEGAERT, Karel</creatorcontrib><creatorcontrib>HOLFORD, Nicholas H. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ANDERSON, Brian J</au><au>ALLEGAERT, Karel</au><au>HOLFORD, Nicholas H. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Population clinical pharmacology of children : modelling covariate effects</atitle><jtitle>European journal of pediatrics</jtitle><addtitle>Eur J Pediatr</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>165</volume><issue>12</issue><spage>819</spage><epage>829</epage><pages>819-829</pages><issn>0340-6199</issn><eissn>1432-1076</eissn><coden>EJPEDT</coden><abstract>Population modelling using mixed effects models provides a means to study variability in paediatric drug responses among individuals representative of those in whom the drug will be used clinically.
Explanatory covariates explain the predictable part of the between-individual variability. Growth and development are two major aspects of children not seen in adults. These aspects can be investigated by using size and age as covariates. Problems attributable to co-linearity can be approached by using size as the first covariate. Size standardisation is achieved using allometric scaling, a mechanistic approach that has a strong theoretical and empirical basis. Age is used to describe the maturation of clearance. The quantitative models (linear, exponential, first-order, variable slope sigmoidal) used to describe this maturation process vary depending on the span of the ages under investigation. Measures of response are not always straightforward and can be more difficult to quantify in children.
Covariate investigation in children is improving the understanding of developmental aspects of drug disposition and effects in the paediatric population, ultimately leading to more effective use of medications.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>16807729</pmid><doi>10.1007/s00431-006-0189-x</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-6199 |
ispartof | European journal of pediatrics, 2006-12, Vol.165 (12), p.819-829 |
issn | 0340-6199 1432-1076 |
language | eng |
recordid | cdi_proquest_miscellaneous_68978925 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Age Analgesics Biological and medical sciences Body Surface Area Body Weight Child Creatinine Creatinine - blood Fractals General aspects Glomerular Filtration Rate Humans Investigations Medical sciences Metabolic Clearance Rate Metabolism Models, Biological Pediatrics Pharmacodynamics Pharmacokinetics Pharmacology |
title | Population clinical pharmacology of children : modelling covariate effects |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T21%3A14%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Population%20clinical%20pharmacology%20of%20children%20:%20modelling%20covariate%20effects&rft.jtitle=European%20journal%20of%20pediatrics&rft.au=ANDERSON,%20Brian%20J&rft.date=2006-12-01&rft.volume=165&rft.issue=12&rft.spage=819&rft.epage=829&rft.pages=819-829&rft.issn=0340-6199&rft.eissn=1432-1076&rft.coden=EJPEDT&rft_id=info:doi/10.1007/s00431-006-0189-x&rft_dat=%3Cproquest_cross%3E68978925%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221911987&rft_id=info:pmid/16807729&rfr_iscdi=true |